Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Esperion Therapeutics Inc (NASDAQ: ESPR) was $2.04 for the day, down -2.86% from the previous closing price of $2.1. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 4.01 million shares were traded. ESPR stock price reached its highest trading level at $2.14 during the session, while it also had its lowest trading level at $2.03.
Ratios:
Our analysis of ESPR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 17 ’25 when Looker Benjamin sold 1,304 shares for $1.13 per share. The transaction valued at 1,470 led to the insider holds 399,937 shares of the business.
Halladay Benjamin sold 11 shares of ESPR for $12 on Jul 17 ’25. The Chief Financial Officer now owns 474,462 shares after completing the transaction at $1.11 per share. On Jul 17 ’25, another insider, Looker Benjamin, who serves as the Officer of the company, bought 1,304 shares for $1.13 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 411310944 and an Enterprise Value of 935524928. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.53. Its current Enterprise Value per Revenue stands at 3.489 whereas that against EBITDA is -26.471.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.88, which has changed by 0.15909088 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 49.60%, while the 200-Day Moving Average is calculated to be 23.25%.
Shares Statistics:
ESPR traded an average of 4.64M shares per day over the past three months and 5780100 shares per day over the past ten days. A total of 200.16M shares are outstanding, with a floating share count of 196.97M. Insiders hold about 2.31% of the company’s shares, while institutions hold 48.88% stake in the company. Shares short for ESPR as of 1753920000 were 23127867 with a Short Ratio of 4.98, compared to 1751241600 on 24026028. Therefore, it implies a Short% of Shares Outstanding of 23127867 and a Short% of Float of 11.6000004.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate the current performance of Esperion Therapeutics Inc (ESPR) in the stock market.The consensus estimate for the next quarter is $0.24, with high estimates of $0.62 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.04, with 6.0 analysts recommending between $0.35 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $96.7M to a low estimate of $58.7M. As of the current estimate, Esperion Therapeutics Inc’s year-ago sales were $51.63MFor the next quarter, 7 analysts are estimating revenue of $146.69M. There is a high estimate of $210.2M for the next quarter, whereas the lowest estimate is $65.3M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $439.4M, while the lowest revenue estimate was $236.52M, resulting in an average revenue estimate of $367.2M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $341.59M in the next fiscal year. The high estimate is $396.8M and the low estimate is $263.6M.